Are routinely collected NHS administrative records suitable for endpoint identification in clinical trials? Evidence from the West of Scotland coronary prevention study by Barry, Sarah J. E. et al.
Barry, Sarah J. E. and Dinnett, Eleanor and Kean, Sharon and Gaw, Allen 
and Ford, Ian (2013) Are routinely collected NHS administrative records 
suitable for endpoint identification in clinical trials? Evidence from the 
West of Scotland coronary prevention study. PLoS ONE, 8 (9). ISSN 
1932-6203 , http://dx.doi.org/10.1371/journal.pone.0075379
This version is available at https://strathprints.strath.ac.uk/63803/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
Are Routinely Collected NHS Administrative Records
Suitable for Endpoint Identification in Clinical Trials?
Evidence from the West of Scotland Coronary Prevention
Study
Sarah J. E. Barry1*, Eleanor Dinnett2, Sharon Kean1, Allan Gaw3, Ian Ford1
1 Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom, 2 R&D Department, Greater Glasgow and Clyde Health Board, Glasgow, United
Kingdom, 3Wellcome Trust/Wolfson Clinical Research Facility, Queen’s University Belfast, Belfast, United Kingdom
Abstract
Background: Routinely collected electronic patient records are already widely used in epidemiological research. In this work
we investigated the potential for using them to identify endpoints in clinical trials.
Methods: The events recorded in the West of Scotland Coronary Prevention Study (WOSCOPS), a large clinical trial of
pravastatin in middle-aged hypercholesterolaemic men in the 1990s, were compared with those in the record-linked deaths
and hospitalisations records routinely collected in Scotland.
Results: We matched 99% of fatal study events by date. We showed excellent matching (97%) of the causes of fatal
endpoint events and good matching (.80% for first events) of the causes of nonfatal endpoint events with a slightly lower
rate of mismatching of record linkage than study events (19% of first study myocardial infarctions (MI) and 4% of first record
linkage MIs not matched as MI). We also investigated the matching of non-endpoint events and showed a good level of
matching, with .78% of first stroke/TIA events being matched as stroke/TIA. The primary reasons for mismatches were
record linkage data recording readmissions for procedures or previous events, differences between the diagnoses in the
routinely collected data and the conclusions of the clinical trial expert adjudication committee, events occurring outside
Scotland and therefore being missed by record linkage data, miscoding of cardiac events in hospitalisations data as
‘unspecified chest pain’, some general miscoding in the record linkage data and some record linkage errors.
Conclusions: We conclude that routinely collected data could be used for recording cardiovascular endpoints in clinical
trials and would give very similar results to rigorously collected clinical trial data, in countries with unified health systems
such as Scotland. The endpoint types would need to be carefully thought through and an expert endpoint adjudication
committee should be involved.
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Introduction
There is increasing interest in the use of routinely collected
health records to support clinical trials. In England, the Clinical
Practice Research Datalink [1] and in Wales, the Secure
Anonymised Information Linkage [2] initiative, support re-
searchers in conducting studies. In Scotland, the Wellcome
Trust funded Scottish Health Informatics Programme [3] has
created a Scotland-wide research platform for the collation and
analysis of electronic patient records. At the same time, there is
a desire to reduce the complexity and cost of conducting clinical
trials. In the United States, the Clinical Trials Transformation
Initiative [4] has been established to drive forward changes in
this area. In the United Kingdom, the Academy of Medical
Sciences has put forward proposals for improvement of the
research environment including increased use of routinely
collected health data. Recently, the Medical Research Council
and other major funders in the UK have created of a network
of four health eResearch Centres as centres of excellence in
research using e-health records.
The future success of the UK Biobank [5] project will depend in
large part on achieving reliable follow-up for clinical outcomes at
reasonable cost. The widely used Scottish Longitudinal Study [6]
and the England & Wales (ONS) Longitudinal Study [7] are based
on linking census data with routinely collected data such as deaths
and hospital admissions, and have led to research in a wide range
of areas, from health services research to employment (eg. [8,9]).
Routinely collected data has been linked to nurse/researcher-
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collected data in the Scottish Health Survey, to follow up
individuals for outcomes that would be resource intensive to
collect by other means [10], and such data has been used to
highlight risk factors to the physical and mental health of the
Scottish population [11,12]. All of these databases are available for
research, whether it be for public health or clinical trial follow-up.
An important question is whether routinely collected data,
especially data collected for administrative reasons, are fit for
purpose as outcomes in clinical trials or epidemiological studies.
In 2007 we were able to extend the original average follow-up of
approximately 5 years in the West of Scotland Coronary
Prevention Study (WOSCOPS) by approximately 10 years [13]
using computer record linkage to nationally held datasets for
hospital admission, incident cancers and deaths in Scotland.
WOSCOPS was a randomised double-blind placebo-controlled
trial of pravastatin in 6595 hypercholesterolaemic men aged 45–64
with no history of myocardial infarction, carried out between 1988
and 1995. The study achieved 100% follow-up of all participants
for vital status at the end of the trial. The main endpoints of the
trial included definite or suspect coronary heart disease (CHD)
death, definite or suspect nonfatal myocardial infarction (MI),
other cardiac death, other vascular death or other death. Further
details on the design and conduct of the trial may be found
elsewhere [14].
The results in the original report of the trial [15] were obtained
via intensive and expensive follow-up of participants and detailed
recording and adjudication of all clinical outcomes. In the current
work we have carried out record linkage follow-up of outcomes
during the trial period, and explored the pros and cons of record
linkage versus intensive follow-up in the context of cardiovascular
endpoints. This research adds detail to an initial assessment of the
utility of record linkage data for general serious adverse event
reporting [16] and shows that it could also be used to follow
patients up on specific endpoints, particularly if an endpoint
committee were involved.
Methods
Overview
Approximately 10 years after the end of the trial, WOSCOPS
participants were probabilistically matched using name, date of
birth and postcode to national datasets for mortality, incident
cancer and hospital discharges by the Information Services
Division (ISD) of the NHS National Services Scotland, providing
computerised record linkage follow-up of all trial participants at
low cost.
This paper compares and contrasts the events that were
reported by the normal trial processes and the events that were
identified by record linkage as occurring during the period of
the trial. We focus on deaths, non-fatal MI and non-fatal stroke.
Ethics Statement
The participants in WOSCOPS provided written informed
consent for access to their medical records, but at the time this did
not explicitly refer to medical records held on a computer. After
the end of the trial, the ethics committee of the Royal Infirmary,
Glasgow, approved linkage of patient information to the partic-
ipants’ electronic medical records. In addition the Privacy
Advisory Committee of National Services Scotland, which acts
as the gatekeeper to Scotland’s national holdings of patient records
and advises ISD, also approved this linkage. Both approvals are
necessary before a linkage can be performed. These processes are
long established in Scotland as the appropriate pathway for record
linkage approvals. Hence, we have strictly adhered to all existing
ethical and information governance requirements in Scotland. In
addition all data were handled in compliance with the UK data
protection regulations.
WOSCOPS Trial Events
During the study, all deaths and all non-fatal coronary events
were reviewed by an endpoint adjudication committee. Although
not pre-specified as an endpoint, potential stroke or transient
ischaemic attack (TIA) events were also documented on a stroke-
specific form and were reviewed centrally at the end of the study
and classified as stroke, TIA or ‘other’. Imaging was not always
available; hence we have not further grouped these events as
haemorrhagic or non-haemorraghic. The original WOSCOPS
definition of a nonfatal MI included events that were ‘silent’ (only
detected via an annual study electrocardiogram without accom-
panying symptoms) or ‘unrecognised’ (symptoms consistent with
an MI detected but not recognised as an MI at the time). Since the
events in the routinely collected dataset were, by definition,
hospitalisations, we included only hospitalised study events in the
analysis, excluding silent events but including unrecognised
hospitalised events. Events originally classified as ‘definite’ or
‘suspect’ were merged. Nonfatal events considered plausibly an MI
were adjudicated as either a nonfatal MI or as a nonfatal ‘other’
event.
Record Linkage (RL) Events
Death records during the trial provided the date of death, an
underlying cause of death and a total of up to four causes coded
using the International Classification of Diseases (ICD) codes,
version 9. For RL identified deaths, cause of death was taken to be
the assigned underlying cause of death.
The Scottish Morbidity Records of hospitalisations contain the
dates of admission and discharge from hospital, along with dates of
ward transfers and up to six diagnoses for each ward stay, all ICD
coded. For analyses involving non-fatal MI, stroke or transient
ischaemic attack (TIA), a relevant code in any position of a
hospitalisation report was taken as evidence of an event.
Hemiplegia was included as a cerebrovascular (stroke/TIA)
diagnosis in the RL dataset.
We searched in the RL dataset for all events recorded as MI. In
the absence of MI, any code for CHD in any position was taken as
evidence of a CHD-related event. In the absence of a CHD code,
a cardiovascular (CV) code in any position identified a CV-related
outcome, and in the absence of a CV code the event was
considered non-cardiovascular. The ICD code groupings for
events identified by RL are given in Appendix S1.
Statistical Methods
WOSCOPS and RL events for an individual were considered to
be the same event if they had a diagnosis match and the event
dates were within at most two weeks of one another. A detailed
study of any WOSCOPS events unmatched in the RL data was
carried out using the patient casenotes. ‘First events’ were defined
as first events of the particular type (eg. MI) during the study
period.
The analysis of the original WOSCOPS events was carried out
for the fatal and hospitalised nonfatal WOSCOPS events, and
similarly for the RL events. These analyses used the log-rank test
to calculate the p-values and Cox proportional hazards models to
produce the risk reduction estimates and corresponding 95%
confidence intervals.
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Results
The baseline characteristics of the participants in the WOS-
COPS are given in Table 1. Participants were on average 55 years
of age and had mean baseline total cholesterol and low density
lipoprotein cholesterol levels of 7.0 and 5.0 mmol/l respectively.
The main original results of the WOSCOPS are given in
Table 2, alongside results excluding non-hospitalised MI and those
obtained using RL outcomes. While the observed risk reduction in
the primary endpoint of CHD death or nonfatal MI was slightly
greater using the RL data than the original or hospitalised
WOSCOPS data, the qualitative conclusion would have been the
same regardless of the approach. A similar impact is observed for
nonfatal MI alone, while the risk reduction for CHD death is
slightly reduced, going from being marginally significant using the
original or hospitalised WOSCOPS events to marginally nonsig-
nificant using the RL events.
Fatal Events
There were 241 deaths recorded in WOSCOPS and 240 in the
RL dataset. Of these 238 were matched by date. Three
WOSCOPS deaths were missing from the RL dataset and further
investigation showed that they all occurred outside Scotland (1
Bulgaria, 2 England). Two deaths were found in the RL dataset
but not recorded in WOSCOPS and these appeared to be errors
in the linkage, since one had a date of death prior to the
participant’s randomisation date and thus could not be the same
person, while the other had no recorded events in WOSCOPS.
The primary causes of death for the 238 deaths that matched
are given in Table 3. The RL data distinguished between 29
‘other’ and 91 ‘cancer’ deaths (which are all denoted as ‘other’ in
the table), with 2 of the ‘other’ deaths being mismatched as CHD
and 1 cancer death as ‘other vascular’ in WOSCOPS. There was a
high rate of matching on cause of death, with only 7/238 (2.9%) of
causes being mismatched. A clinical review of the death certificates
for these 7 patients, blinded to the WOSCOPS outcome, re-
Table 1. Baseline characteristics.
Characteristic Placebo (N=3293) Pravastatin (N=3302)
Continuous variables (mean (SD))
Age (years) 55.1 (5.5) 55.3 (5.5)
Body Mass Index (kg/m2) 26.0 (3.1) 26.0 (3.2)
Systolic Blood Pressure (mmHg) 136 (17) 135 (18)
Diastolic Blood Pressure (mmHg) 84 (10) 84 (11)
Total cholesterol (mmol/l) 7.0 (0.6) 7.0 (0.6)
LDL cholesterol (mmol/l) 5.0 (0.4) 5.0 (0.4)
HDL cholesterol (mmol/l) 1.1 (0.3) 1.1 (0.2)
Triglycerides (mmol/l) 1.85 (0.77) 1.83 (0.79)
Categorical variables (n (%))
+ve Rose Questionnaire (angina) 174 (5%) 164 (5%)
+ve Rose Questionnaire (claudication) 96 (3%) 97 (3%)
Diabetes mellitus 35 (1%) 41 (1%)
Hypertension 506 (15%) 531 (16%)
Current smoker 1460 (44%) 1445 (44%)
Former Smoker 1127 (34%) 1138 (34%)
Never smoker 705 (21%) 717 (22%)
Baseline characteristics of the WOSCOPS population split by treatment group.
doi:10.1371/journal.pone.0075379.t001
Table 2. Original WOSCOPS results and corresponding results using hospitalised WOSCOPS and Record Linkage events.
Original WOSCOPS events Hospitalised WOSCOPS events Record Linkage events
Endpoint
type
Placebo
(n=3293)
Pravastatin
(n =3302) P
%RR
(95% CI)
Placebo
(n =3293)
Pravastatin
(n=3302) P
%RR
(95% CI)
Placebo
(n =3293)
Pravastatin
(n =3302) P
%RR
(95% CI)
CHD death
or MI
295 (9.3) 215 (6.5) ,0.001 29 (15, 44) 212 (6.7) 147 (4.6) ,0.001 32 (16,45) 195 (6.1) 121 (3.8) ,0.001 39 (24,51)
Nonfatal MI 246 (7.8) 182 (5.8%) 0.001 27 (12, 40) 156 (4.9) 112 (3.6) 0.005 29 (10,45) 143 (4.5) 87 (2.7) ,0.001 40 (22,54)
CHD death 61 (1.9) 41 (1.3) 0.042 33 (1,55) – – – – 56 (1.7) 40 (1.3) 0.093 29 (-6,53)
Original results from the WOSCOPS study (combining definite and suspect coronary events) compared with those omitting non-hospitalised myocardial infarction (MI)
and with results based entirely on record linkage. Data shown are numbers and rates (%) of events for each treatment group, p-value and % risk reduction (RR) for the
outcomes of coronary heart disease (CHD) death or MI, non fatal MI and CHD death.
doi:10.1371/journal.pone.0075379.t002
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classified 4 of the events, reducing the mismatch rate to 3/238
(1%).
Nonfatal Events
The distribution of RL events conditional on WOSCOPS
MI events. There were 304 cases of nonfatal MI incurring
hospitalisation in WOSCOPS, 268 of which were first hospitalised
MI events. Table 4 shows the distributions of corresponding RL
events for first and subsequent WOSCOPS MI events.
The matching of MI events is better for first than subsequent
events, with 81.4% of WOSCOPS first MI events versus 58.3% of
subsequent MI events matching with MI events in RL. The
classification rate of WOSCOPS MI events as CHD events
(including MI) is similar for first and subsequent events, however,
with 89.6% and 91.6% concordance, respectively. Of particular
note is that over half of the WOSCOPS MI events not matched
with cardiovascular events in RL (15/25 of first and 2/3 of
subsequent nonmatched events) were matched with RL events
diagnosed as non-cardiac ‘unspecified chest pain’, suggesting that
there may be a number of miscodings for such events in hospital
records. Of the 9 WOSCOPS MI events that were not found at all
in the RL dataset, 7 of the events occurred outside Scotland, 1
patient was admitted to a private hospital (only NHS admissions
are recorded in the hospitalisations dataset) and 1 was definitely
admitted to hospital according to the casenotes and their absence
from the hospitalisations dataset is presumed due to linkage errors.
The distribution of WOSCOPS MI events conditional on
RL MI events. Of the 264 hospitalisations identified in RL as
MI, 230 were first events, and 96.0% of these were matched with a
WOSCOPS MI event (Table 5). A total of 7 (3.0%) first RL MI
events were matched with ‘other’ events in WOSCOPS, all of
which had been adjudicated by the WOSCOPS adjudication
committee as not being MI events. Of the 10 (29.4%) subsequent
events matched with ‘other’ events in WOSCOPS, 9 were
similarly adjudicated as not being MI events, while one had MI
as the secondary diagnosis to a primary diagnosis of chest pain and
the patient casenotes showed it involved a procedure following an
earlier (matched) MI and was therefore not a ‘true’ MI admission.
Of the 2 (0.9%) first event hospitalisations with an MI diagnosis
that were not matched with WOSCOPS MI endpoint events, the
patient casenotes showed that one was a day admission for a
procedure and the other was admitted with atrial fibrillation and
had been confirmed to the trial committee by the patient’s
cardiologist as having no evidence of MI. Neither event, therefore,
was referred to the endpoint committee.
Of the 6 (17.6%) subsequent event hospitalisations with an MI
diagnosis that were not matched with WOSCOPS MI endpoint
events, the patient casenotes show that 3 were readmissions
following matched MI events (one involving a procedure), 1 was a
transfer from a private hospital following an earlier admission for a
MI (and therefore not a true admission), 1 was admitted to
Accident & Emergency only and diagnosed with heart failure and
1 was admitted for pulmonary oedema. None of these events were
referred to the endpoint committee.
Distribution of RL events conditional on a WOSCOPS
stroke or TIA. There were a total of 94 WOSCOPS events for
stroke or TIA, 83 of which were first stroke/TIA events, and the
level of matching with RL events is shown in Table 6. Of the
WOSCOPS first stroke events, 78.7% were matched with either
RL stroke (72.1%) or TIA hospitalisations (6.6%). For WOSCOPS
first TIA events, the match rate was similar at 77.2% (54.5%
matched as TIA, 22.7% as stroke).
Of the WOSCOPS stroke/TIA first events, 12 were completely
unmatched, of which 6 occurred outside Scotland, 1 was an
admission to a private hospital, 1 was missing supporting
documentation to confirm their admission date, 3 had definite
admissions with stroke/TIA diagnoses, suggesting a possible
problem with RL, coding or admission dates and 1 had
unspecified cerebrovascular disease. There were only 11 instances
of subsequent WOSCOPS stroke/TIA events, all of which were
matched in RL.
Distribution of WOSCOPS events conditional on a RL
stroke or TIA. Table 7 shows that there were a total of 102
hospitalisations in the RL data for stroke or TIA events, 87 of
which were first events. Of the RL first stroke events, 83.1% were
matched with either WOSCOPS stroke (75.4%) or TIA (7.7%)
events. For RL first TIA events, the matching rate was slightly
Table 3. Matching of the causes of death between WOSCOPS
and Record Linkage.
Record Linkage cause of death
WOSCOPS cause
of death CHD
Other
cardiac
Other
vascular Other Total
CHD 96 1 1 2 100
Other cardiac 0 3 0 0 3
Other vascular 0 2 15 1 18
Other 0 0 0 117 117
Total 96 6 16 120 238
Comparison of WOSCOPS death classification with Record Linkage classification
in the 238 deaths identified by both approaches. ‘Other’ and ‘cancer’ Record
Linkage deaths have been combined into a single ‘other’ category.
doi:10.1371/journal.pone.0075379.t003
Table 4. Matching of WOSCOPS first and subsequent MI events with corresponding Record Linkage events.
Record Linkage events
1st MI Subsequent MI CHD CVD CP Other Non-match Total
First WOSCOPS
MI event
217 (81.0%) 1 (0.4%) 22 (8.2%) 3 (1.1%) 15 (5.6%) 2 (0.7%) 8 (3.0%) 268
Subsequent
WOSCOPS event
4 (11.1%) 17 (47.2%) 12 (33.3%) 0 (0.0%) 2 (5.6%) 0 (0.0%) 1 (2.8%) 36
Total 221 (72.7%) 18 (5.9%) 34 (11.2%) 3 (1.0%) 17 (5.6%) 2 (0.6%) 9 (3.0%) 304
WOSCOPS first and subsequent MI events matched with Record Linkage events by cause and date (MI =myocardial infarction; CHD=Coronary Heart Disease;
CVD=other cardiovascular disease; CP = non-cardiac chest pain). ‘Other’ matches are for a ’date matched’ event with a diagnosis other than MI, CHD, CVD or CP and
non-matches have no near date match.
doi:10.1371/journal.pone.0075379.t004
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lower at 72.7% (54.5% as TIA, 18.2% as stroke). There was a
higher level of mismatching of a small number of subsequent
stroke/TIA events.
The RL stroke/TIA events that were matched with MI
endpoints had both MI and stroke/TIA diagnoses for the same
hospitalisation. Of the 15 ‘other’ matches and the non-matches for
RL first stroke or TIA events in record linkage, 6 were capturing a
pre-existing condition according to the patient notes, 2 were
capturing a cerebral event other than stroke/TIA, 4 had unclear
diagnosis or the diagnosis was clarified later, 1 was not an acute
event and 2 were unexplained and may have been due to
inaccurate coding or additional information in the medical record.
Of the 9 ‘other’ matches and the non-matches for RL subsequent
stroke or TIA events, 8 were capturing a pre-existing condition,
while for 1 the event was recorded on the case report forms in
WOSCOPS but the specific stroke/TIA form was not completed.
Discussion
It is clear that, if WOSCOPS had only considered fatal events
and nonfatal events that incurred hospitalisation, the researchers
would have drawn very similar conclusions using record linkage
data only compared to using adjudicated outcomes. We have
shown, for cardiovascular data collected in Scotland, good
matching of routinely collected and rigorously collected clinical
trial data, in particular for mortality. The matching was also good
for MI endpoints, particularly for first events. The quality of
matching was less good for the stroke and TIA non-endpoint
events.
Due to the imperfect matching of events, our proposed model of
conducting a cardiovascular clinical trial using RL data in a
unified healthcare system would be to use RL for case finding and
to have an expert endpoint committee that would adjudicate based
on appropriate source documentation from the patient’s clinical
record. Based on our results we believe that this model would be
likely to detect most of the MI events that were coded in the
hospitalisations dataset as CHD or cardiovascular events. It would
also be likely to eliminate most of the spurious ‘events’ that were
actually hospital transfers or readmissions for procedures following
a previous event. We have also identified that a number of MI or
other cardiac events may be miscoded as unspecified chest pain in
the hospital admission record, suggesting that including this
diagnosis when searching for cardiac events would increase the
rate of detection, although possibly at the expense of a significant
amount of additional case record review.
Events occurring outside of Scotland were a minor issue. Cross-
linking with other nations within the UK would reduce this
problem further. Events occurring outside the UK, other than
deaths reported in UK death registries, or hospital cases
transferred back to UK hospitals, would go undetected. However,
the level of under-reporting present in the RL data was low and
would be unlikely to have a substantial effect on the outcome of a
trial.
The quality of matching of hospitalised stroke and TIA events
was poorer since this type of event may be more likely to be
Table 5. Matching of Record Linkage first and subsequent MI events with corresponding WOSCOPS events.
WOSCOPS events
1st MI Subsequent MI Other Non-match Total
First RL MI event 217 (94.3%) 4 (1.7%) 7 (0.3%) 2 (0.9%) 230
Subsequent RL event 1 (2.9%) 17 (50.0%) 10 (29.4%) 6 (17.6%) 34
Total 218 (82.6%) 21 (8.0%) 17 (6.4%) 8 (3.0%) 264
Record Linkage first and subsequent MI events matched with WOSCOPS events. ‘Other’ matches correspond to a date match with events adjudicated by the
adjudication committee as not being MI, and non-matches had no near date match.
doi:10.1371/journal.pone.0075379.t005
Table 6. Matching of the WOSCOPS strokes and TIAs.
Record Linkage events
First WOSCOPS event Stroke TIA MI Other Non-match Total
Stroke 44 (72.1%) 4 (6.6%) 1 (1.6%) 4 (6.6%) 8 (13.1%) 61
TIA 5 (22.7%) 12 (54.5%) 1 (4.5%) 0 (0.0%) 4 (18.2%) 22
Total 49 (59.0%) 16 (19.3%) 2 (2.4%) 4 (4.8%) 12 (14.5%) 83
Record Linkage events
Subsequent WOSCOPS event Stroke TIA MI Other Non-match Total
Stroke 10 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 10
TIA 0 (0.0%) 1 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1
Total 10 (90.9%) 1 (9.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 11
Matching of WOSCOPS first and subsequent strokes and transient ischaemic attacks (TIA) by cause and date with Record Linkage events. The ‘other’ RL events were any
hospitalizations with a date match but a diagnosis other than stroke, TIA or MI and non-matches had no near date match. A first event was defined as either a stroke or a
TIA event and could match with a first or subsequent event of the opposing type.
doi:10.1371/journal.pone.0075379.t006
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misdiagnosed or miscoded. Nevertheless, RL picked up most of
the WOSCOPS events, and the larger numbers of events that
were recorded in the hospitalisations dataset than in WOSCOPS
were mainly due to investigations or procedures for pre-existing
conditions or previous events, issues that would be mostly resolved
by case record review. It must also be borne in mind that stroke
was not a specified endpoint in WOSCOPS and so we would
expect a lower level of matching here due to a potentially less
rigorous process of recording such events within the trial.
Clearly, in designing a clinical trial using RL data to detect
clinical cardiovascular events, choice of endpoint would have to be
made carefully. General cardiovascular or coronary hospitalisa-
tions are likely to be identified with high sensitivity and specificity.
More focussed event types (such as MI or stroke) are likely to
benefit from the use of RL for case identification followed by case
note extraction and expert review.
In summary, we have shown that the wealth of routinely
collected data could be used for cardiovascular outcome detection
in a clinical trial carried out in a country with a unified health
system, such as Scotland or the wider UK, and would likely lead to
a qualitatively similar outcomes to those obtained by the current
expensive clinical trial model involving rigorous individual patient
follow-up and intensive data collection.
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Table 7. Matching of the Record Linkage strokes and TIAs.
WOSCOPS event
First Record Linkage event Stroke TIA MI Other Non-match Total
Stroke 49 (75.4%) 5 (7.7%) 1 (1.5%) 2 (3.1%) 8 (12.3%) 65
TIA 4 (18.2%) 12 (54.5%) 1 (4.8%) 1 (4.5%) 4 (18.2%) 22
Total 53 (60.9%) 17 (19.5%) 2 (2.3%) 3 (3.4%) 12 (13.8%) 87
WOSCOPS event
Subsequent Record Linkage event Stroke TIA MI Other Non-match Total
Stroke 5 (38.5%) 0 (0.0%) 0 (0.0%) 1 (7.7%) 7 (53.8%) 13
TIA 0 (0.0%) 1 (50.0%) 0 (0.0%) 0 (0.0%) 1 (50.0%) 2
Total 5 (33.3%) 1 (6.7%) 0 (0.0%) 1 (6.7%) 8 (53.3%) 15
Matching of Record Linkage events for stroke and TIA with WOSCOPS events. The ‘other’ WOSCOPS events were date matches that were originally recorded as MI in
WOSCOPS but were adjudicated by the expert committee as not being an MI, and non-matches had no near date match. A first event was defined as either a stroke or a
TIA event and could match with a first or subsequent event of the opposing type.
doi:10.1371/journal.pone.0075379.t007
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